Saint Nobel Biotech: The Approval Notice for the listing application of Linalopeptide API has been obtained.

Sheng Nuo Biology announced that its wholly-owned subsidiary, Chengdu Sheng Nuo Bio-Pharmaceutical Co., Ltd., recently received the "Notice of Approval for the Marketing Application of Chemical Raw Materials for Lanalotide" issued by the National Medical Products Administration. Lanalotide is mainly used for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. The raw material has completed DMF filing with the FDA in the United States. This approval will enrich the company's raw material product line, facilitate the expansion of sales, accumulate experience, and enhance competitiveness. However, the sales of the drug are subject to uncertainties related to policies, market conditions, and other factors.